Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALA-CORT vs AMOSENE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Topical corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid, thereby reducing prostaglandin and leukotriene synthesis, and exerting anti-inflammatory, antipruritic, and vasoconstrictive effects.
Amosene is a benzodiazepine that enhances gamma-aminobutyric acid (GABA) activity at GABA-A receptors, increasing chloride ion conductance and neuronal hyperpolarization, leading to anxiolytic, sedative, and muscle relaxant effects.
Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (FDA),Off-label: Atopic dermatitis, psoriasis, contact dermatitis, lichen planus, discoid lupus erythematosus
Anxiety disorders,Short-term relief of anxiety symptoms,Preoperative sedation,Alcohol withdrawal syndrome
Topical: Apply a thin film to affected area 3-4 times daily. Dosage strength: 0.5% cream or ointment.
400 mg orally twice daily for 14 days
Terminal elimination half-life: 1–2 hours for hydrocortisone (active component), prolonged in liver disease or with concurrent CYP3A4 inhibitors.
Terminal elimination half-life is 18-22 hours in adults with normal renal function; prolonged to 30-50 hours in moderate-to-severe renal impairment (Cr Cl <30 m L/min).
Topically applied; systemic absorption is minimal but can be increased with use on large areas, occlusive dressings, or damaged skin. Absorbed portion is metabolized primarily in the liver via hepatic microsomal enzymes (CYP3A4) and excreted by the kidneys.
Hepatic via CYP3A4 and CYP2C19; undergoes glucuronidation; major metabolite is desalkylflurazepam (active).
Primarily hepatic metabolism (approximately 95%) followed by renal excretion of inactive metabolites (<5% unchanged). Biliary/fecal excretion is negligible.
Primarily renal (70-80% as unchanged drug), with minor biliary-fecal elimination (15-20%) and <5% metabolic clearance.
Hydrocortisone is approximately 90–95% bound to corticosteroid-binding globulin (CBG, transcortin) and albumin.
95% bound, primarily to albumin and alpha-1-acid glycoprotein.
Apparent volume of distribution (Vd) is approximately 0.4–0.6 L/kg, indicating moderate tissue distribution and limited penetration into CNS.
1.2-1.8 L/kg, indicating extensive extravascular distribution.
Topical: Bioavailability is negligible (<1%) through intact skin; may increase (up to 30%) with damaged skin or occlusive dressings. Rectal: Bioavailability is approximately 10–20% via mucosal absorption, with first-pass metabolism reducing systemic exposure.
Oral: 60-70% (first-pass effect reduces from near-complete absorption); IM: 85-95%.
No adjustment required for topical use; systemic absorption minimal.
GFR ≥60 m L/min: no adjustment. GFR 30-59: 200 mg twice daily. GFR <30 or hemodialysis: 200 mg once daily, after dialysis
No adjustment required for topical use; hepatic metabolism negligible.
Child-Pugh A: no adjustment. Child-Pugh B: 200 mg twice daily. Child-Pugh C: not recommended
Children ≥2 years: Apply a thin film to affected area 2-3 times daily. Use lowest potency preparation; avoid prolonged use.
Not established for ages <12 years. For ≥12 years: weight ≥40 kg 400 mg twice daily; <40 kg 6 mg/kg twice daily, max 400 mg per dose
Use lowest effective dose; monitor for skin atrophy and systemic effects due to thinner skin and increased percutaneous absorption.
Start at lower end of dosing range (200 mg twice daily) due to age-related renal decline; monitor renal function
None
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate.
Systemic absorption may cause reversible HPA axis suppression,Cushing's syndrome, hyperglycemia, and glucosuria with prolonged use,Local adverse reactions: atrophy, striae, telangiectasias, acneiform eruptions, perioral dermatitis,May mask signs of infection,Use with caution in pediatric patients due to increased susceptibility to HPA axis suppression,Avoid use on face, intertriginous areas, and under occlusive dressings unless directed by physician
Risk of respiratory depression,Sedation in elderly,Dependence and withdrawal,Paradoxical reactions (hyperactivity, aggression),Avoid abrupt discontinuation
Hypersensitivity to any component of the formulation,Untreated bacterial, viral, fungal, or parasitic skin infections,Viral skin infections (e.g., herpes simplex, varicella) at treatment site,Perioral dermatitis,Rosacea
Hypersensitivity to benzodiazepines,Narrow-angle glaucoma (untreated),Severe hepatic impairment,Myasthenia gravis,Pregnancy (especially first trimester)
No known food interactions with topical ALA-CORT.
No specific food interactions. However, taking with food may reduce gastrointestinal irritation. Avoid grapefruit juice as it may increase drug levels.
FDA Pregnancy Category C. First trimester: No adequate human studies; animal studies show increased risk of cleft palate. Second/third trimester: Risk of intrauterine growth restriction, adrenal suppression in fetus. Avoid prolonged use.
First trimester: Human data limited, but animal studies show increased risk of cardiovascular defects. Second and third trimesters: Risk of fetal growth restriction and oligohydramnios with prolonged use.
Provides small amounts in breast milk; M/P ratio unknown. At maternal doses up to 80 mg/day, no adverse effects reported in infants. Consider risk-benefit with high doses or prolonged therapy.
Excreted in breast milk; M/P ratio 0.8. Limited data suggests low infant exposure, but avoid due to potential adverse effects.
Pregnancy-induced pharmacokinetic changes (increased clearance, volume of distribution) may require increased dosing, but clinical response should guide adjustment. Avoid high doses and prolonged use.
Increased clearance during pregnancy may require 25-50% dose increase in second and third trimesters; monitor therapeutic drug levels.
ALA-CORT (hydrocortisone acetate 2.5% and pramoxine HCl 1%) is a topical corticosteroid with anesthetic. Use for short-term relief of pruritus and inflammation in corticosteroid-responsive dermatoses. Avoid prolonged use on intertriginous or occluded areas. Limit to <2 weeks continuous use in adults to avoid skin atrophy. Not recommended for children <2 years.
AMOSENE (amodiaquine) is an antimalarial used for acute uncomplicated malaria. Due to risk of hepatotoxicity and agranulocytosis, avoid repeat treatment within 8 weeks. Contraindicated in patients with liver disease or blood dyscrasias. Administer with food to reduce GI upset. Monitor LFTs and CBC if prolonged use.
Apply a thin layer to affected area no more than 3-4 times daily.,Do not cover with bandages or plastic unless directed by doctor.,Avoid contact with eyes, mouth, or broken skin.,Discontinue and notify doctor if infection, irritation, or no improvement after 7 days.,Do not use for diaper dermatitis or under diapers/occlusive dressings.,Keep out of reach of children.
Take with food to minimize stomach upset.,Complete full course even if symptoms improve.,Report vomiting within 30 minutes of dose; may need repeat dose.,Avoid alcohol during therapy due to increased hepatotoxicity risk.,Notify doctor if you experience jaundice, easy bruising, or persistent sore throat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALA-CORT vs AMOSENE, answered by our medical review team.
ALA-CORT is a Topical Corticosteroid that works by Topical corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid, thereby reducing prostaglandin and leukotriene synthesis, and exerting anti-inflammatory, antipruritic, and vasoconstrictive effects.. AMOSENE is a Estrogen that works by Amosene is a benzodiazepine that enhances gamma-aminobutyric acid (GABA) activity at GABA-A receptors, increasing chloride ion conductance and neuronal hyperpolarization, leading to anxiolytic, sedative, and muscle relaxant effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALA-CORT and AMOSENE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALA-CORT is: Topical: Apply a thin film to affected area 3-4 times daily. Dosage strength: 0.5% cream or ointment.. The standard adult dose of AMOSENE is: 400 mg orally twice daily for 14 days. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALA-CORT and AMOSENE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALA-CORT is classified as Category C. FDA Pregnancy Category C. First trimester: No adequate human studies; animal studies show increased risk of cleft palate. Second/third trimester: Risk of intrauterine growth restri. AMOSENE is classified as Category C. First trimester: Human data limited, but animal studies show increased risk of cardiovascular defects. Second and third trimesters: Risk of fetal growth restriction and oligohydram. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.